World J Mens Health.  2020 Apr;38(2):139-140. 10.5534/wjmh.190129.

Prostate Cancer Mortality and Use of 5-Alpha Reductase Inhibitors

• Foldes CA
• Wang R
• Canfield S

• KMID: 2471820
• DOI: http://doi.org/10.5534/wjmh.190129

Abstract

No abstract available.

MeSH Terms

5-alpha Reductase Inhibitors*
Mortality*
Prostate*
Prostatic Neoplasms*
5-alpha Reductase Inhibitors

Reference

1. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011; 306:1549–1556. PMID: 21990298.

2. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349:215–224. PMID: 12824459.

3. Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007; 99:1366–1374. PMID: 17848668.

4. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362:1192–1202. PMID: 20357281.

5. Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, McKay RR, et al. Association of treatment with 5α-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern Med. 2019; 179:812–819. PMID: 31058923.

6. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998; 52:195–201. PMID: 9697781.

7. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006; 98:1128–1133. PMID: 16912265.